Acadia Seeks FDA Approval For Genetic Neurological Disorder Candidate
July 18, 2022 at 16:53 PM EDT
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ...
